The Report entitled 2019-2026 Global Erythropoietin (EPO) Drug Market Report explores the essential factors of the Erythropoietin (EPO) Drug market considering such as industry situations, market demands, market players adopted business strategies and their growth scenario. The Global Erythropoietin (EPO) Drug market has been separated by this report based on the key players profiles, Type, Application and Regions.
Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO-stimulating agents as these diseases may cause anemia. To curb rising incidence of anemia, demand for erythropoietin drugs is expected to increase over the coming years.
Download Sample Copy of this Report @ https://dataintelo.com/request-sample/?reportId=722
One of the major reasons for anemia is Chronic Kidney Diseases (CKD). Rising incidence of CKD is the key contributing factor responsible for the growing demand. According to statistics published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 661,000 people are affected by kidney failures in the U.S. and the number is projected to increase in the near future. This is anticipated to fuel the demand for the market further.
Erythropoietin, also known as hemotopoietin, is a hormone produced by the kidneys for the continuous production of red blood cells.
The global erythropoietin drug market report by Market Research Future (MRFR) has been compiled after undertaking painstaking primary and secondary research.
According to the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK), close to 661,000 people were diagnosed with chronic kidney disease.
This can fuel the demand for EPO drugs in the market.The large cases of ESRD has caused a surge of anemia among patients and portended to fuel the demand for erythropoietin drugs.
Approval of Epogen and commercialization of the drug as early as 2016 has facilitated market growth.
Low cost of therapeutics in developing economies of APAC and MEA will facilitate segment growth.By application, it is segmented into HIV, oncology, renal diseases, and others.On the basis of end user, it is divided into hospital and pharmacy.
It is a glycoprotein hormone that controls erythropoiesis or production of RBC.
Moreover, introduction of new drugs and different government initiatives for research fuels the market growth during the forecast period.Global erythropoietin drug market is growing with the rapid pace.
According to a recent study report published by the Market Research Future, global erythropoietin drug market is booming and expected to gain prominence over the forecast period.
The market is projected to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).Global erythropoietin drug market is expected to grow at a CAGR of 9.5% during forecasted period.Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1360Erythropoietin Drug Market Key PlayersThe global erythropoietin drug market is observed to be growing rapidly owing to increasing developments of key players like Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Amgen (US), Kyowa Hakko Kirin, Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India), Celltrion, Inc. (South Korea), Hospira (US), Dahua Pharmaceutical (China), LG Life Sciences Ltd. (Korea), 3SBio, Boehringer Ingelheim (US), BIOSIDUS (Argentina).Erythropoietin Drug Market SegmentationGlobal erythropoietin drug market is segmented on the basis of type of product into biosimilars, first generation formulation and second generation formulation.
On the basis of application market is segmented as oncology, renal diseases, HIV and other and on the basis of end user they are segmented into hospital and pharmacy.Erythropoietin Drug Market Regional AnalysisNorth America has the largest market share in global erythropoietin drug market owing to the increasing population of people suffering from cancer and renal diseases.
Erythropoietin drug market in Europe is growing owing to the development of numerous biosimilars which in turn increases the frequency of their usage.
The Business Research Company’s latest report Erythropoietin (EPO) Global Market Report 2020 covers Erythropoietin (EPO) market drivers, Erythropoietin (EPO) market trends, Erythropoietin (EPO) market segments, Erythropoietin (EPO) market growth rate, Erythropoietin (EPO) market major players, and Erythropoietin (EPO) market size.
The report provides in-depth analysis of the impact of COVID-19 on the Erythropoietin (EPO) industry, along with revised market numbers due to the effects of the coronavirus.View Complete Report:https://www.thebusinessresearchcompany.com/report/erythropoietin-epo-global-market-report-2020-30-covid-19-growth-and-change Erythropoietin (EPO) Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
The chapter also covers markets which have been positively affected by the pandemic.Request for the sample now:https://www.thebusinessresearchcompany.com/sample.aspx?id=3436=smpThe global erythropoietin (EPO) market is expected to decline from $1.01 billion in 2019 to $0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%.
The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges.
The entire supply chain has been disrupted, impacting the market negatively.
